期刊文献+

甲状腺超声血流指数与肿瘤恶性程度的相关性研究 被引量:3

Correlation between thyroid ultrasound blood flow index and malignant degree of tumors
在线阅读 下载PDF
导出
摘要 目的:研究甲状腺超声血流指数(FI)与肿瘤恶性程度的关系。方法:选择2015年2月—2018年5月在我院接受手术切除的甲状腺癌患者和甲状腺腺瘤患者,分别作为观察组和对照组。术前进行甲状腺超声并测定FI,采集血清并测定肿瘤相关细胞角蛋白19片段(CYFRA21-1)、肿瘤相关物质(TAM)、基质金属蛋白酶9(MMP9)的含量;术后收集病灶并测定基因PCNA、Ki-67、CyclinD1、p53、PTEN的表达水平。结果:观察组FI水平(43.12±6.62)明显高于对照组(33.41±6.62);观察组中AJCCⅢ~Ⅳ期、组织分化Ⅲ期、有颈淋巴结转移、有包膜浸润患者的FI水平明显高于AJCCⅠ~Ⅱ期、组织分化Ⅰ~Ⅱ期、无颈淋巴结转移、无包膜浸润患者(P<0.05);高FI甲状腺癌患者血清Cyfra21-1、TAM、MMP9含量以及病灶内PCNA、Ki-67、CyclinD1的阳性表达率均明显高于低FI甲状腺癌患者,高FI甲状腺癌患者病灶内p53、PTEN的阳性表达率明显低于低FI甲状腺癌患者(P<0.05)。结果:甲状腺超声FI能够反应甲状腺癌的临床病理特征及恶性程度。 Objective:To study the correlation between thyroid ultrasound blood flow index(FI)and malignant degree of tumors.Methods:Patients with thyroid cancer and thyroid adenoma who underwent surgical resection in our hospital from February 2015 to May 2018 were selected as observation group and control group.Thyroid ultrasound were conducted and FI were measured before operation.Serum samples were collected and cytokeratin 19 fragments(CYFRA21-1)and tumo associated material(TAM)and matrix metalloproteinase 9(MMP9)levels were determined;the lesions were collected and the expression levels of PCNA,Ki-67,CyclinD1,p53 and PTEN were determined.Results:The FI level of patients in the observation group was(43.12±6.62),which was significantly higher than(33.41±6.62)of the control group;the FI level of patients with AJCC III-IV stage,tissue differentiation III stage,cervical lymph node metastasis and capsular infiltration in the observation group was significantly higher than that of patients with AJCC I-II stage,tissue differentiation I-II stage,no cervical lymph node metastasis and no capsular infiltration(P<0.05).The serum levels of Cyfra21-1,TAM,MMP9 and the positive expression rates of PCNA,Ki-67 and CyclinD 1 in high FI thyroid cancer patients were significantly higher than those in low FI thyroid cancer patients,and the positive expression rates of p53 and PTEN in lesions were significantly lower than those in low FI thyroid cancer patients(P<0.05).Results:Thyroid ultrasound FI could reflect the clinicopathological features and malignant degree of thyroid cancer.
作者 郑晓宏 杜振双 黄慧玲 张少波 胡清福 王清茂 ZHENG Xiao-hong;DU Zhen-shuang;HUANG Hui-ling;ZHANG Shao-bo;HU Qing-fu;WANG Qing-mao(Department of General Surgery,the 910 Hospital of the Chinese People's Liberation Army(Quanzhou 362000,China;Department of General Practice,the Fujian Medical University 2nd Affiliated Hospital(Quanzhou 362000,China;Department of General Surgery,the Shishi Hospital(Shishi 362700,China)
出处 《中国现代普通外科进展》 CAS 2019年第12期954-957,共4页 Chinese Journal of Current Advances in General Surgery
基金 2014年南京军区医学科技创新项目(14ZX12)。
关键词 甲状腺肿瘤 超声 血流指数 肿瘤标志物 Thyroid cancer Ultrasound Blood flow index Tumor markers
作者简介 郑晓宏(1984-09~),福建泉州人,主治医师,研究方向:甲状腺乳腺外科。E-mail:65777478@qq.com;通信作者:王清茂(1965-06~),福建石狮人,主任医师,研究方向:甲状腺乳腺外科、胃肠外科。E-mail:wangqm567@163.com。
  • 相关文献

参考文献14

二级参考文献114

  • 1张勤良,关琪.海藻玉壶汤对甲状腺癌荷瘤小鼠趋化因子受体CXCR4的影响研究[J].中国生化药物杂志,2014,34(2):42-44. 被引量:9
  • 2万里,郑旭琴.SATB1在甲状腺癌中的表达及促进甲状腺癌侵袭能力的实验研究[J].中国生化药物杂志,2014,34(6):17-20. 被引量:18
  • 3王晓辉,张浩,叶棋浓.癌基因和抑癌基因研究进展[J].生物技术通讯,2006,17(2):242-244. 被引量:4
  • 4赖非云,张诠,杨传盛,郭朱明,吴秋良,许光普,曹云.Bcl-2在甲状腺癌组织中的表达及意义[J].实用癌症杂志,2007,22(6):600-602. 被引量:8
  • 5Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide in- creasing incidence of thyroid cancer: update on epidemiol- ogy and risk factors [ J ]. J Cancer Epidemiol, 2013,2013 (7) :1 - 10.
  • 6Appetecchia M, Mequle A, et al. Serum cytokeratins de- termination in differentiated thyroid carcinoma [ J ]. Exp Clin Cancer Res,2001,20(2) :253 - 256.
  • 7Giovanella L, Ceriani L, Ghelfo A, et al. Circulating cytok- eratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland[ J]. Int J Biol Markers, 2008,23( 1 ) :54 -57.
  • 8Isice Savin S,Cveji6 D,et al,Serum Cyfra 21.1 and ga- lectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors[J].cer Res Clin Oncol, 2010, 136 (12) :1805 - 1812.
  • 9Makki FM, Taylor SM, Shahnavaz A, et al. Serum biomar- kers of papillary thyroid cancer [J].olaryngol Head Neck Surg,2013,42(16) :1 - 10.
  • 10Giovanella L,Treglia G,Verburg FA, et al. Serum cytok- eratin 19 fragments: a dedifferentiation marker in ad- vanced thyroid cancer [ J ]. Eur Endocrinol, 2012, 167 (6) :793 -797.

共引文献145

同被引文献31

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部